首页> 美国卫生研究院文献>BMC Genomics >Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery
【2h】

Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery

机译:金黄色分枝杆菌和替代模型物种与结核分枝杆菌的表型和基因组比较:对药物发现的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTuberculosis (TB) is caused by Mycobacterium tuberculosis and represents one of the major challenges facing drug discovery initiatives worldwide. The considerable rise in bacterial drug resistance in recent years has led to the need of new drugs and drug regimens. Model systems are regularly used to speed-up the drug discovery process and circumvent biosafety issues associated with manipulating M. tuberculosis. These include the use of strains such as Mycobacterium smegmatis and Mycobacterium marinum that can be handled in biosafety level 2 facilities, making high-throughput screening feasible. However, each of these model species have their own limitations.
机译:背景结核病(TB)是由结核分枝杆菌引起的,它代表着全球药物发现计划面临的主要挑战之一。近年来细菌耐药性的显着上升导致对新药和药物疗法的需求。定期使用模型系统来加快药物发现过程,并规避与操纵结核分枝杆菌有关的生物安全性问题。这些措施包括使用可在生物安全性2级设施中处理的诸如耻垢分枝杆菌和海洋分枝杆菌等菌株,从而使高通量筛选成为可能。但是,每个模型物种都有其自身的局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号